CA2779473C - Methods of treating viral associated diseases - Google Patents
Methods of treating viral associated diseases Download PDFInfo
- Publication number
- CA2779473C CA2779473C CA2779473A CA2779473A CA2779473C CA 2779473 C CA2779473 C CA 2779473C CA 2779473 A CA2779473 A CA 2779473A CA 2779473 A CA2779473 A CA 2779473A CA 2779473 C CA2779473 C CA 2779473C
- Authority
- CA
- Canada
- Prior art keywords
- virus
- cmx001
- cells
- compound
- jcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25670109P | 2009-10-30 | 2009-10-30 | |
| US61/256,701 | 2009-10-30 | ||
| US32699110P | 2010-04-22 | 2010-04-22 | |
| US32698610P | 2010-04-22 | 2010-04-22 | |
| US32698210P | 2010-04-22 | 2010-04-22 | |
| US32698910P | 2010-04-22 | 2010-04-22 | |
| US61/326,986 | 2010-04-22 | ||
| US61/326,982 | 2010-04-22 | ||
| US61/326,991 | 2010-04-22 | ||
| US61/326,989 | 2010-04-22 | ||
| US32747410P | 2010-04-23 | 2010-04-23 | |
| US61/327,474 | 2010-04-23 | ||
| US32791410P | 2010-04-26 | 2010-04-26 | |
| US61/327,914 | 2010-04-26 | ||
| US32849110P | 2010-04-27 | 2010-04-27 | |
| US61/328,491 | 2010-04-27 | ||
| US33062410P | 2010-05-03 | 2010-05-03 | |
| US61/330,624 | 2010-05-03 | ||
| US33170410P | 2010-05-05 | 2010-05-05 | |
| US61/331,704 | 2010-05-05 | ||
| US35543010P | 2010-06-16 | 2010-06-16 | |
| US61/355,430 | 2010-06-16 | ||
| US40507510P | 2010-10-20 | 2010-10-20 | |
| US40508010P | 2010-10-20 | 2010-10-20 | |
| US40507310P | 2010-10-20 | 2010-10-20 | |
| US40508410P | 2010-10-20 | 2010-10-20 | |
| US61/405,080 | 2010-10-20 | ||
| US61/405,075 | 2010-10-20 | ||
| US61/405,084 | 2010-10-20 | ||
| US61/405,073 | 2010-10-20 | ||
| PCT/US2010/054779 WO2011053812A1 (en) | 2009-10-30 | 2010-10-29 | Methods of treating viral associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2779473A1 CA2779473A1 (en) | 2011-05-05 |
| CA2779473C true CA2779473C (en) | 2016-08-16 |
Family
ID=43922582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2779473A Active CA2779473C (en) | 2009-10-30 | 2010-10-29 | Methods of treating viral associated diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130072458A1 (enExample) |
| EP (1) | EP2493479A4 (enExample) |
| JP (1) | JP2013509433A (enExample) |
| AU (1) | AU2010313273B2 (enExample) |
| CA (1) | CA2779473C (enExample) |
| WO (1) | WO2011053812A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN102670628B (zh) | 2008-01-25 | 2015-11-25 | 奇默里克斯公司 | 治疗病毒感染的方法 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| HUE032860T2 (en) * | 2010-02-12 | 2017-11-28 | Chimerix Inc | A method for treating a virus infection |
| US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
| ES2604137T3 (es) | 2010-08-31 | 2017-03-03 | Chimerix, Inc. | Derivados de éster de fosfonato y métodos de síntesis de los mismos |
| CA2853720A1 (en) * | 2011-10-26 | 2013-05-02 | Chimerix, Inc. | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| CA2857490C (en) | 2011-12-22 | 2020-03-31 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| EP2841162A4 (en) * | 2012-04-27 | 2016-02-24 | Chimerix Inc | METHOD FOR CONTROLLING VIRUS ASSOCIATED ENDORGANIC DAMAGE |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| US9526729B2 (en) * | 2013-01-29 | 2016-12-27 | Hsiao Lily Yu | Medicament for treating peripheral neuropathies |
| EP3401320B1 (en) | 2013-03-15 | 2020-05-13 | The Regents of the University of California | Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia |
| BR112016010862B1 (pt) | 2013-11-15 | 2022-11-29 | Chimerix, Inc | Formas mórficas de ésteres de hexadeciloxipropilfosfonato, seu método de preparo e composição compreendendo a dita forma mórfica |
| RS63250B1 (sr) | 2014-09-15 | 2022-06-30 | Univ California | Nukleotidni analozi |
| WO2016069630A1 (en) | 2014-10-27 | 2016-05-06 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters bearing at least one deuterium atom |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| WO2017196990A1 (en) * | 2016-05-12 | 2017-11-16 | Contravir Pharmaceuticals, Inc. | Methods of treating hepatitis b infections and related dosage regimes |
| EP3474822B1 (en) | 2016-06-28 | 2025-07-09 | Emergent BioDefense Operations Lansing LLC | Formulations of brincidofovir |
| WO2018156879A1 (en) * | 2017-02-23 | 2018-08-30 | Chimerix, Inc. | Treatment of adenovirus with brincidofovir |
| JP7369143B2 (ja) * | 2018-12-25 | 2023-10-25 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤 |
| US20220184164A1 (en) * | 2019-03-29 | 2022-06-16 | Evonik Operations Gmbh | Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae |
| CN117285565A (zh) * | 2022-06-24 | 2023-12-26 | 润佳(苏州)医药科技有限公司 | 核苷类似物及其医药用途 |
| CA3262284A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| JP4942915B2 (ja) * | 2002-04-26 | 2012-05-30 | ギリアード サイエンシーズ, インコーポレイテッド | Hivプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積 |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US20080020018A1 (en) * | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
| US8642577B2 (en) * | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| EP2125024B1 (en) * | 2007-03-23 | 2013-02-13 | TO-BBB Holding B.V. | Targeted intracellular delivery of antiviral agents |
| EP2155257B1 (en) * | 2007-04-27 | 2016-10-05 | Chimerix, Inc. | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
| EP2462152A4 (en) * | 2009-08-03 | 2013-02-13 | Chimerix Inc | COMPOSITION AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS AND TEMPORED VIRUSES |
| US20110263536A1 (en) * | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
-
2010
- 2010-10-29 CA CA2779473A patent/CA2779473C/en active Active
- 2010-10-29 EP EP10827544.7A patent/EP2493479A4/en not_active Ceased
- 2010-10-29 WO PCT/US2010/054779 patent/WO2011053812A1/en not_active Ceased
- 2010-10-29 AU AU2010313273A patent/AU2010313273B2/en active Active
- 2010-10-29 JP JP2012537128A patent/JP2013509433A/ja active Pending
- 2010-10-29 US US13/504,785 patent/US20130072458A1/en not_active Abandoned
-
2014
- 2014-11-14 US US14/542,295 patent/US20150141375A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013509433A (ja) | 2013-03-14 |
| US20150141375A1 (en) | 2015-05-21 |
| CA2779473A1 (en) | 2011-05-05 |
| WO2011053812A1 (en) | 2011-05-05 |
| EP2493479A1 (en) | 2012-09-05 |
| AU2010313273B2 (en) | 2015-04-02 |
| US20130072458A1 (en) | 2013-03-21 |
| AU2010313273A1 (en) | 2012-05-24 |
| EP2493479A4 (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2779473C (en) | Methods of treating viral associated diseases | |
| US20120164104A1 (en) | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | |
| US12414961B2 (en) | Substituted nucleosides and nucleotides for treating viral infections | |
| ES2915381T3 (es) | Análogos de nucleótidos | |
| AU2024205205A1 (en) | Methods for treating SARS CoV-2 infections | |
| JP6220484B1 (ja) | フィロウイルス科ウイルス感染症を処置するための方法 | |
| JP2021517132A (ja) | 4’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| WO2014124430A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| EP2770834A1 (en) | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection | |
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| US20190085013A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CN102665729A (zh) | 用于治疗病毒相关性疾病的方法 | |
| EP3077403A1 (en) | Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof | |
| AU2015203573A1 (en) | Methods of treating viral associated diseases | |
| AU2015264949A1 (en) | Composition and methods of treating viral infections and viral induced tumors | |
| HK1240226B (en) | Nucleotide analogs | |
| HK1240226A1 (en) | Nucleotide analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |